TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biophytis SA ( (FR:ALBPS) ) has shared an update.
Biophytis SA announced its participation in the 15th International Conference on Frailty and Sarcopenia Research, where it will present preliminary data on BIO101 for treating obesity-associated sarcopenia. This participation underscores Biophytis’s commitment to advancing treatments for age-related diseases and highlights its role in the scientific community focused on frailty and sarcopenia.
More about Biophytis SA
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Their lead drug candidate, BIO101, is being developed for muscular diseases, respiratory diseases, and metabolic disorders. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis is listed on Euronext Growth Paris and the OTC market.
YTD Price Performance: -14.57%
Average Trading Volume: 7,225
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €4.61M
See more insights into ALBPS stock on TipRanks’ Stock Analysis page.